delveinsight-discount
DelveInsight Blog
Related Article

Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19
Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555. LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...
Find More
Introducing a new brand identity, and a new website: DelveInsight.
Today we’re unveiling a new identity and launching a new logo. For any company, to get a new logo designed might look like a cakewalk; however, it is exactly the opposite. This is a big deal because we are highly recognized by our old one in our industry, among our clients, employees, business partners, an...
Find More
Gold Nanoparticles May Soon Treat Prostate Cancer
Gold nanoparticles may soon turn out to be a Prostate cancer treatment option. Apparently, there are certain risks associated with conventional cancer treatments such as uncontrolled bleeding, fatal blood clots and dangerous reactions to the anaesthetic, among others. To relieve patients from such risks, a new clini...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.